ReviewProgress in neuro-psychopharmacology & biological psychiatry2017
Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: Past, present, and future.
Review in Progress in neuro-psychopharmacology & biological psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Diagnostic accuracy of miRNAs in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis.Frontiers in public health · 2025Pooled it
- Uncoupling neocortical neuron fate and migration via a Let-7-RBX2 axis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- MicroRNAs as Regulators, Biomarkers, and Therapeutic Targets in Autism Spectrum Disorder.Molecular neurobiology · 2025Review
- An In Vitro Study for the Role of Schizophrenia-Related Potential miRNAs in the Regulation of COMT Gene.Molecular neurobiology · 2024Article
- Post-transcriptional dysregulation in autism, schizophrenia, and bipolar disorder.Journal of biomedical research · 2024Article
- Genetically predicted fatty liver disease and risk of psychiatric disorders: A mendelian randomization study.World journal of clinical cases · 2024Article
- Quantitative proteomics of the miR-301a/SOCS3/STAT3 axis reveals underlying autism and anxiety-like behavior.Molecular therapy. Nucleic acids · 2024Article
- Exploring mood disorders and treatment options using human stem cells.Genetics and molecular biology · 2024Article
- A characteristic cerebellar biosignature for bipolar disorder, identified with fully automatic machine learning.IBRO neuroscience reports · 2023Article
- Bipolar disorder-iPSC derived neural progenitor cells exhibit dysregulation of store-operated CaMolecular psychiatry · 2023Article
- Blood miRNA levels associated with ADHD traits in children across six European birth cohorts.BMC psychiatry · 2023Article
- Pharmacological Mechanism of Ketamine in Suicidal Behavior Based on Animal Models of Aggressiveness and Impulsivity: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Mapping miRNA Research in Schizophrenia: A Scientometric Review.International journal of molecular sciences · 2022Review
- MicroRNAs, Stem Cells in Bipolar Disorder, and Lithium Therapeutic Approach.International journal of molecular sciences · 2022Review
- miR-218: A Stress-Responsive Epigenetic Modifier.Non-coding RNA · 2022Review
- miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders.The pharmacogenomics journal · 2022Review
- Identification of microRNAs associated with human fragile X syndrome using next-generation sequencing.Scientific reports · 2022Article
- Micro-RNAs, the Cornerstones of the Future of Radiobiology in Head and Neck Cancers?Current oncology (Toronto, Ont.) · 2022Review
- Baiap3 regulates depressive behaviors in mice via attenuating dense core vesicle trafficking in subsets of prefrontal cortex neurons.Neurobiology of stress · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Neuropsychiatric disorders are common health problems affecting approximately 1% of the population. Twin, adoption, and family studies have displayed a strong genetic component for many of these disorders; however, the underlying pathophysiological mechanisms and neural substrates remain largely unknown. Given the critical need for new diagnostic markers and disease-modifying treatments, expanding the focus of genomic studies of neuropsychiatric disorders to include the role of non-coding RNAs (ncRNAs) is of growing interest. Of known types of ncRNAs, microRNAs (miRNAs) are 20-25-nucleotide, single-stranded, molecules that regulate gene expression through post-transcriptional mechanisms and have the potential to coordinately regulate complex regulatory networks. In this review, we summarize the current knowledge on miRNA alteration/dysregulation in neuropsychiatric disorders, with a special emphasis on schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD). With an eye toward the future, we also discuss the diagnostic and prognostic potential of miRNAs for neuropsychiatric disorders in the context of personalized treatments and network medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.